# Intravitreous Bevacizumab and Standard Metabolic Control for Diabetic Macular Edema - A Contrast Sensitivity Study

> **NCT02308644** · PHASE3 · COMPLETED · sponsor: **University of Sao Paulo** · enrollment: 41 (actual)

## Conditions studied

- Diabetic Macular Edema

## Interventions

- **DRUG:** intravitreal bevacizumab injection(1.25mg)

## Key facts

- **NCT ID:** NCT02308644
- **Lead sponsor:** University of Sao Paulo
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-02
- **Primary completion:** 2011-12
- **Final completion:** 2013-02
- **Target enrollment:** 41 (ACTUAL)
- **Last updated:** 2014-12-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02308644

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02308644, "Intravitreous Bevacizumab and Standard Metabolic Control for Diabetic Macular Edema - A Contrast Sensitivity Study". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02308644. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*